Submit Manuscript

International Journal of Pharmacology

Year: 2005 | Volume: 1 | Issue: 4 | Page No.: 342-345
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

ABSTRACT

This study was designed to investigate the effects of sandostatin LAR after multiple injections and duration of its effect on acromegal patients. Five acromegal patients were treated with sandostatin LAR. After performing Octreotide test, 30 mg sandostatin LAR was administered for 3 times and the frequency of mean daily Growth Hormone (GH) less than 5μg L-1 were compared between 1st and 3rd injections. Then drug’s acting period was assessed (G.H <5 μg L-1). In addition in 3 patients the efficacy of 30 and 40 mg daily dosages were compared with each other. No significant relationship was found between the response rate to sandostatin and short acting Octreotide. Also the frequency of GH <5 μg L-1 after 3rd injection was more than scale after the first injection (p<0.01). The drug’s effect continued for at least 42 days after injections. Octreotide test (with single dose injection) wasn’t proved to be a reliable method for prediction of patients` response to treatment. Measuring GH after multiple injections is a better method for this purpose and it`s also better to determine injection intervals in each patient individually.
PDF References Citation

REFERENCES

  1. Ross, D.A. and C.B. Wilson, 1996. Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. J. Neurosurg., 68: 854-867.
  2. Fahlbusch, R., J. Honegger and W. Schott, 1994. Results of surgery in acromegaly. Treating acromegaly. Bristol. J. Endocrinol., 23: 49-54.
  3. Alexander, L., D. Appleton and R. Hall, 1997. Epidemiology of acromegaly in the newcastle region. Clin. Endocrinol., 12: 71-79.
  4. Bengtsson, B.A., S. Eden and T. Ernest, 1986. Epidemiology and long-term survival in acromegaly: A study of 166 cases diagnosed between 1955 and 1984. Acta Med. Scandinavica, 223: 327-335.
  5. Rajasoorya, C., I.M. Holdway and P. Wrightson, 1995. Determinants of clinical outcome and survival in acromegaly. Clin. Endocrinol., 121: 478-483.
  6. Ezzart, S., P.J. Snyder and W.F. Young, 1998. Octreotide treatment of acromegaly: A randomized, multicenter study. Ann. Internal Med., 117: 711-718.
  7. Newman. B., S. Melmed and P.J. Snyder, 1999. Safety and efficacy of long term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients a clinical research center study. J. Clin. Endocrinol. Metab., 80: 2768-2775.
  8. Stewart, P.M., K.F. Kane and S.E. Stewart, 1997. Depot long-acting somatostatin analog (sandostatin-LAR) is an effective treatment for acromegaly. J. Clin. Endocrinol. Metab., 80: 3267-3272.
  9. Bevan, J.S., S.L. Atkin and A.B. Atkinson, 1996. Primary medical therapy for acromegaly: An open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I and tumor size. J. Clin. Endocrinol. Metab., 87: 4554-4563.
  10. Ayuk, J., S.E. Stewart and P.M. Stewart, 1995. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J. Clin. Endocrinol. Metab., 87: 4142-4146.
  11. Colao, A., D. Ferone and P. Marzullo, 1999. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J. Clin. Endocrinol. Metab., 86: 2779-2786.
  12. Biermasz, N.R., N.C. Vanden-Oever and M. Frolich, 1998. Sandostatin LAR in acromegaly: A 6-week injection interval suppresses GH secretion as effectively as a 4 week interval. Clin. Endocrinol., 58: 288-295.
  13. Colao, A., P. Marzullo and A. Cuocolo, 2000. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin. Endocrinol., 58: 169-176.
  14. Colao, A., S. Cannavo and P. Marzullo, 1998. Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. Eur. J. Endocrinol., 148: 131-138.
  15. Szucs, N., J. Meszaros and S. Czirjak, 2002. Experience in treating acromegalic patients with long-acting octreotide. Orvosi Hetilap, 143: 1066-1070.
    PubMedDirect Link
  16. Vance, M.C. and A.G. Harris, 1991. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the international multicenter acromegaly study group. Arch. Internal Med., 151: 1573-1578.
    Direct Link
  17. Tauber, J.P., T.H. Babin and M.T. Tauber, 2000. Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly. J. Clin. Endocrinol. Metab., 68: 917-924.
  18. Hunter, S.J., J.A., J.A. Shaw and K.O. Lee, 1997. Comparison of monthly intramuscular injections of sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly, effects on growth hormone and other markers of growth hormone secretion. Clin. Endocrinol., 50: 245-257.
  19. Grass, P., P. Marbach and C. Bruns, 1999. Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: Pharmacokinetic and pharmacodynamic relationships. Metabolism, 45: 27-30.
  20. Jenkins, P., S. Akker and S.L. Chew, 2001. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clin. Endocrinol., 53: 719-724.
  21. Stewart, P.M., S.E. Stewart and P.M.S. Clark, 2000. Clinical and biochemical response following withdrawal of long-acting, depot injection form of octreotide sandostatin-LAR. Clin. Endocrinol., 50: 295-299.
  22. Flogstad, A.K., J. Halse and T. Haldorsen, 2001. Sandostatin LAR in acromegalic patients: A dose-range study. J. Endocrinol. Metab., 80: 3601-3607.
  23. Laws, Jr. E.R., S.M. Carpenter and B.W. Scheithauer, 1987. Long Term Results of Transsphenoidal Surgery for the Management of Acromegaly. In: Acromegaly: A Century of Scientific and Clinical Progress, Robbins, R. and S. Melmed (Eds.). Plenum Press, New York, USA., pp: 241-248.

Leave a Reply

Your email address will not be published. Required fields are marked *